Ending deaths from HIV-related cryptococcal meningitis by 2030

Amir Shroufi, Tom Chiller, Alex Jordan, David W. Denning, Thomas S. Harrison, Nelesh P. Govender, Angela Loyse, Solange Baptiste, Radha Rajasingham, David R. Boulware, Isabela Ribeiro, Joseph N. Jarvis, Gilles Van Cutsem

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)16-18
Number of pages3
JournalThe Lancet Infectious Diseases
Volume21
Issue number1
DOIs
StatePublished - Jan 2021

Bibliographical note

Funding Information:
AS reports personal fees from Drugs for Neglected Diseases Initiative and Centers for Disease Control and Prevention Foundation, outside the submitted work. DWD and family hold founder shares in F2G, a University of Manchester spin-out antifungal discovery company. DWD acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, Bright Angel Therapeutics, and Metis. In the past 3 years, DWD has been paid for talks on behalf of Dynamiker Biotechnology, Hikma Pharmaceuticals, Gilead Sciences, Merck, Mylan, and Pfizer. DWD is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology, and Infectious Diseases Aspergillosis Guidelines group. TSH reports grants from the UK Medical Research Council, French National Agency for Research on AIDS and Viral Hepatitis, European and Developing Countries Clinical Trials Partnership, and Gilead Sciences; personal fees from Gilead Sciences and Pfizer; and non-financial support from ImmunoMycologics, outside the submitted work. NPG reports grants from the National Institutes of Health, UK Medical Research Council, Bill & Melinda Gates Foundation, Centers for Disease Control and Prevention, and National Health Laboratory Service Research Trust, outside the submitted work. AL reports grants from European and Developing Countries Clinical Trials Partnership, outside the submitted work. RR reports grants from National Institute of Allergy and Infectious Diseases, during the conduct of the study. JNJ reports grants from European and Developing Countries Clinical Trials Partnership, National Institute for Health Research, National Institutes of Health, and UK Medical Research Council, outside the submitted work. All other authors declare no competing interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention.

Cite this